Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of peripheral blood lymphocyte subsets in critical patients at ICU admission: A preliminary investigation of their role in the prediction of sepsis during ICU stay.
Frattari A, Polilli E, Primiterra V, Savini V, Ursini T, Di Iorio G, Parruti G. Frattari A, et al. Among authors: parruti g. Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418792310. doi: 10.1177/2058738418792310. Int J Immunopathol Pharmacol. 2018. PMID: 30114952 Free PMC article.
Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report.
Parruti G, Frattari A, Polilli E, Savini V, Sciacca A, Consorte A, Cibelli DC, Agostinone A, Di Masi F, Pieri A, Cacciatore P, Di Iorio G, Fazii P, Spina T. Parruti G, et al. J Med Case Rep. 2019 Jan 22;13(1):20. doi: 10.1186/s13256-018-1934-2. J Med Case Rep. 2019. PMID: 30665450 Free PMC article.
Control of Gram-negative multi-drug resistant microorganisms in an Italian ICU: Rapid decline as a result of a multifaceted intervention, including conservative use of antibiotics.
Frattari A, Savini V, Polilli E, Di Marco G, Lucisano G, Corridoni S, Spina T, Costantini A, Nicolucci A, Fazii P, Viale P, Parruti G. Frattari A, et al. Among authors: parruti g. Int J Infect Dis. 2019 Jul;84:153-162. doi: 10.1016/j.ijid.2019.04.002. Int J Infect Dis. 2019. PMID: 31204003 Free article.
Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Among authors: parruti g. Ann Rheum Dis. 2022 Nov;81(11):e215. doi: 10.1136/annrheumdis-2020-218626. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737108 No abstract available.
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
Potere N, Di Nisio M, Rizzo G, La Vella M, Polilli E, Agostinone A, Spacone A, Di Carlo S, Costantini A, Abbate A, Porreca E, Parruti G. Potere N, et al. Among authors: parruti g. Int J Infect Dis. 2020 Nov;100:421-424. doi: 10.1016/j.ijid.2020.07.078. Epub 2020 Aug 6. Int J Infect Dis. 2020. PMID: 32768701 Free PMC article.
Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Among authors: parruti g. Ann Rheum Dis. 2022 Oct;81(10):e195. doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1. Ann Rheum Dis. 2022. PMID: 32873552 No abstract available.
262 results